These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31063776)

  • 1. Pathophysiological clues to therapeutic applications of glutamate mGlu5 receptor antagonists in levodopa-induced dyskinesia.
    Pourmirbabaei S; Dolatshahi M; Rahmani F
    Eur J Pharmacol; 2019 Jul; 855():149-159. PubMed ID: 31063776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.
    Rascol O; Fox S; Gasparini F; Kenney C; Di Paolo T; Gomez-Mancilla B
    Parkinsonism Relat Disord; 2014 Sep; 20(9):947-56. PubMed ID: 24951359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.
    Duty S
    CNS Drugs; 2012 Dec; 26(12):1017-32. PubMed ID: 23114872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
    Morin N; Morissette M; Grégoire L; Di Paolo T
    Curr Neuropharmacol; 2016; 14(5):481-93. PubMed ID: 26639458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
    Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
    J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling.
    Rylander D; Recchia A; Mela F; Dekundy A; Danysz W; Cenci MA
    J Pharmacol Exp Ther; 2009 Jul; 330(1):227-35. PubMed ID: 19357321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
    Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia.
    Sebastianutto I; Cenci MA
    Curr Opin Pharmacol; 2018 Feb; 38():81-89. PubMed ID: 29625424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonism of metabotropic glutamate receptor type 5 prevents levodopa-induced dyskinesia development in a male rat model of Parkinson's disease: Electrophysiological evidence.
    Kamo H; Iwamuro H; Nakamura R; Nojiri S; Okuzumi A; Ogawa T; Nakajima A; Hattori N; Shimo Y
    J Neurosci Res; 2024 Mar; 102(3):e25302. PubMed ID: 38515319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia.
    Maranis S; Stamatis D; Tsironis C; Konitsiotis S
    Eur J Pharmacol; 2012 May; 683(1-3):71-7. PubMed ID: 22410193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias.
    Marin C; Bonastre M; Aguilar E; Jiménez A
    Synapse; 2011 Oct; 65(10):1080-6. PubMed ID: 21484883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamatergic mechanisms in L-DOPA-induced dyskinesia and therapeutic implications.
    Mellone M; Gardoni F
    J Neural Transm (Vienna); 2018 Aug; 125(8):1225-1236. PubMed ID: 29387966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
    Morin N; Morissette M; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Neuropharmacology; 2015 Dec; 99():356-68. PubMed ID: 26254863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa-induced dyskinesia: interplay between the N-methyl-D-aspartic acid receptor and neuroinflammation.
    Zhang F; Liu M; Tuo J; Zhang L; Zhang J; Yu C; Xu Z
    Front Immunol; 2023; 14():1253273. PubMed ID: 37860013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
    Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.
    Tison F; Keywood C; Wakefield M; Durif F; Corvol JC; Eggert K; Lew M; Isaacson S; Bezard E; Poli SM; Goetz CG; Trenkwalder C; Rascol O
    Mov Disord; 2016 Sep; 31(9):1373-80. PubMed ID: 27214664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
    J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.